Hjem › Rhabdomyosarkom › Texas
Rhabdomyosarkom kliniske forsøg i Texas
9 studier for Rhabdomyosarkom søger deltagere på steder i Texas.
Byer i Texas
Officiel studietekst (engelsk)
Phase I Trial to Determine the Dose and Evaluate the PK and Safety of Lutetium Lu 177 Edotreotide Therapy in Pediatric Participants With SSTR-positive Tumors
- University of Texas - MD Anderson Cancer Center, Houston
RekruttererFase 1
24 Months – 18 Years · Alle køn · Opdateret 25. sep. 2026 · NCT06441331Silmitasertib (CX-4945) in Combination With Chemotherapy for Relapsed Refractory Solid Tumors
- Children's Medical Center, Dallas
RekruttererFase 1/2
Op til 30 år · Alle køn · Opdateret 3. sep. 2026 · NCT06541262A Study Comparing Higher Dose Chemotherapy Over a Shorter Amount of Time to Lower Dose Chemotherapy Plus Maintenance Over a Longer Amount of Time in Patients With Newly Diagnosed Intermediate-Risk Rhabdomyosarcoma (IR RMS)
- Dell Children's Medical Center of Central Texas, Austin
- Driscoll Children's Hospital, Corpus Christi
- UT Southwestern/Simmons Cancer Center-Dallas, Dallas
- og 2 flere
RekruttererFase 3
Op til 50 år · Alle køn · Opdateret 25. aug. 2026 · NCT07466316Interleukin-15 and -21 Armored Glypican-3-specific Chimeric Antigen Receptor Expressed in T Cells for Pediatric Solid Tumors
- Texas Children's Hospital, Houston
RekruttererFase 1
Alder 1 til 21 · Alle køn · Opdateret 6. aug. 2026 · NCT04715191PEEL-224, Vincristine and Temozolomide in Pediatric Solid Tumors
- Texas Children's Hospital, Houston
RekruttererFase 1/2
Alder 1 til 30 · Alle køn · Opdateret 22. jul. 2026 · NCT06721689Treatment of Newly Diagnosed Rhabdomyosarcoma Using Molecular Risk Stratification and Liposomal Irinotecan Based Therapy in Children With Intermediate and High Risk Disease
- Cook Children's Medical Center, Fort Worth
RekruttererFase 2
Op til 22 år · Alle køn · Opdateret 15. jun. 2026 · NCT06023641VITAS: Atezolizumab in Combination With Chemotherapy for Pediatric Relapsed/Refractory Solid Tumors
- The University of Texas Southwestern Medical Center, Dallas
- Texas Children's Hospital, Houston
RekruttererFase 1/2
6 Months – 30 Years · Alle køn · Opdateret 2. jun. 2026 · NCT04796012HER2 Chimeric Antigen Receptor (CAR) T Cells in Combination With Checkpoint Blockade in Patients With Advanced Sarcoma
- Texas Children's Hospital, Houston
RekruttererFase 1
Alder 1 til 25 · Alle køn · Opdateret 22. jan. 2026 · NCT04995003Immunotherapy For Adults With GPC3-Positive Solid Tumors Using IL-15 and IL-21 Armored GPC3-CAR T Cells
- Houston Methodist Hospital, Houston
RekruttererFase 1
Op til 21 år · Alle køn · Opdateret 3. nov. 2025 · NCT06198296Fra ClinicalTrials.gov, data hentet 3. okt. 2026. Hver studie har sine egne kvalifikationskrav; studieteamet afgør, hvem der kan deltage.